AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18653121
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid treatment for 60 days
Trial: 2573295
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion after placebo pretreatment
Trial: 2573295
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion after atenolol pretreatment
Trial: 2573295
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion after propranolol pretreatment
Trial: 2573295
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion after beta-2-selective beta-blocking agent (ICI 118551)
Trial: 29561428
Drug: ChondroT 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChondroT 1.0 g
Trial: 29561428
Drug: ChondroT 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChondroT 2.0 g
Trial: 12712245
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g resistant starch (Novelose 260)
Trial: 8658094
Drug: Furosemide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (1 mg/h)
Trial: 24451130
Drug: Lycopene-enriched diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene-enriched diet (20-25 mg/day of lycopene; through 30 g/day of triple concentrated tomato paste) for 6 months
Trial: 12051113
Drug: Estradiol and
RxNorm normalized name: Estradiol and Norgestimate Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol and sequential levonorgestrel (50 micrograms/day estradiol for 2 weeks followed by 50 micrograms/day estradiol-10 micrograms/day levonorgestrel for 2 weeks)
Trial: 12051113
Drug: Estradiol and
RxNorm normalized name: Estradiol and Norgestimate Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol and sequential levonorgestrel (75 micrograms/day estradiol for 2 weeks followed by 75 micrograms/day estradiol-15 micrograms/day levonorgestrel for 2 weeks)
Trial: 12051113
Drug: Estradiol and
RxNorm normalized name: Estradiol and Norgestimate Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol and sequential levonorgestrel (100 micrograms/day estradiol for 2 weeks followed by 100 micrograms/day estradiol-20 micrograms/day levonorgestrel for 2 weeks)
Trial: 12051113
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three doses of the transdermal hormone replacement therapy
Trial: 8652176
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with appropriate selection of drugs, techniques, and needles
Trial: 26198890
Drug: Very early
RxNorm normalized name: Primula veris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very early mobilisation (n=43) consisting of early and frequent out of bed activities starting within 24 hours of stroke onset for 5 to 30 minutes at least twice a day for seven days
Trial: 18757184
Drug: Capsular polysaccharide-based
RxNorm normalized name: CAPSULAR POLYSACCHARIDE,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsular polysaccharide-based vaccine (StaphVAX)
Trial: 18757184
Drug: Human immunoglobulin
RxNorm normalized name: Human immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human immunoglobulin G (IgG) preparation (INH-A21, Veronate)
Trial: 10920157
Drug: Albuterol administered
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol administered through the spacer device (50 microg/kg)
Trial: 10920157
Drug: Albuterol administered
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol administered through the nebulizer (150 microg/kg)
Trial: 10920157
Drug: Albuterol administered
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol administered through the spacer device
Trial: 10920157
Drug: Albuterol administered
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol administered through the nebulizer
Trial: 8936492
Drug: Overnight glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight glucose infusion (5 mg.kg‐1.d‐1)
Trial: 1543310
Drug: Intranasal cocaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine, 2 mg/kg body weight
Trial: 10866909
Drug: Multiple injections
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple injections
Trial: 3904464
Drug: Conventional two-injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional two-injection treatment
Trial: 31289017
Drug: Continuous intracoronary
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intracoronary adenosine (360 mcg/min)
Trial: 31289017
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous adenosine (140-180 mcg/kg/min)
Trial: 27692497
Drug: PHMB-based solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHMB-based solution
Trial: 10704160
Drug: Nitroglycerin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin plus Heparin
Trial: 8263618
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium tocolysis
Trial: 3518729
Drug: Treuphadol oblong
RxNorm normalized name: Cydonia oblonga leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treuphadol oblong tablets (500 mg paracetamol)
Trial: 3518729
Drug: Treuphadol Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treuphadol Plus oblong tablets (500 mg paracetamol, 30 mg codeine phosphate)
Trial: 3518729
Drug: Treuphadol suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treuphadol suppositories (750 mg paracetamol)
Trial: 3518729
Drug: Commercial tablets
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial tablets (500 mg paracetamol)
Trial: 26091965
Drug: DHA-enriched formula
RxNorm normalized name: STRESS FORMULA 500,BIOTIN ENRICHED TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-enriched formula (600 mg daily)
Trial: 25517706
Drug: Nicotine-replacement therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine-replacement therapy for 8 weeks
Trial: 12800126
Drug: Nicotine-replacement therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine-replacement therapy
Trial: 17490963
Drug: Diet containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet containing 550 mg choline x 70 kg(‐1) x d(‐1) for 10 d followed by <50 mg choline x 70 kg(‐1) x d(‐1)
Trial: 17490963
Drug: Diet containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet containing 550 mg choline x 70 kg(‐1) x d(‐1)
Trial: 17490963
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplement (400 microg/d)
Trial: 11079284
Drug: Sumatriptan tablets
RxNorm normalized name: Sumatriptan Tablets
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan tablets
Trial: 1305042
Drug: Ukrain administered
RxNorm normalized name: Ukrain cation
DrugBank: Ukrain cation (DB17150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ukrain administered intramuscularly (i.m.) or intravenously (i.v.) every one, two or three days in doses of 5 to 50 mg for 7 to 40 days
Trial: 1305042
Drug: Ukrain administered
RxNorm normalized name: Ukrain cation
DrugBank: Ukrain cation (DB17150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ukrain administered for three years in the dose of 5 to 50 mg/injection in repeated courses
Trial: 28759833
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E treatment for 8 weeks
Trial: 23764683
Drug: Famotidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (100 mg twice daily, n = 16)
Trial: 21840734
Drug: Maximal dose
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal dose of fluvastatin (80 mg/day)
Trial: 21840734
Drug: Titrated dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated dosing of fluvastatin (starting at 20 mg/day)
Trial: 19640855
Drug: Health promotion
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health promotion programme consisting of three sessions weekly over 12 weeks (one educational session and two physical activity sessions).
Trial: 10701034
Drug: Anaesthetist-administered midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anaesthetist-administered midazolam
Trial: 8989196
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (3.0 to 20 micrograms/kg/min)
Trial: 22520536
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg and Ezetimibe 10 mg
Trial: 18299307
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine mixed with rapid-acting insulin analog, administered twice daily
Trial: 18299307
Drug: Neutral protamine
RxNorm normalized name: Neutral protamine hagedorn insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral protamine Hagedorn (NPH) therapy with rapid-acting insulin analog, administered twice daily
Trial: 16781218
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (ASA)
Trial: 7978599
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg IV naloxone
Trial: 7978599
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg IV naloxone
Trial: 2689916
Drug: Buflomedil chlorhydrate
RxNorm normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buflomedil chlorhydrate (150 mg intravenous injection in bolus)
Trial: 25219982
Drug: Retina Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retina Implant Alpha IMS
Trial: 23860295
Drug: Short-acting β2‐agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting β2‐agonist (SABA) - 20 µg of inhaled procaterol
Trial: 19398092
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg estradiol and 400 mg progesterone
Trial: 19398092
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg estradiol and 400 mg progesterone
Trial: 19398092
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg estradiol and placebo
Trial: 12413372
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (abciximab and half-dose reteplase)
Trial: 12413372
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of reteplase
Trial: 9844098
Drug: Moderate exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate exercise (30-minute sessions of weight-bearing physical education lessons three times weekly for 8 months)
Trial: 7536619
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy for cystic fibrosis, details on dosage and duration not available
Trial: 7536619
Drug: Current treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatments for cystic fibrosis, details on specific treatments not available
Trial: 2574049
Drug: xamoterol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoterol (200 mg twice a day)
Trial: 6993253
Drug: Inhaler with
RxNorm normalized name: albuterol 90 MCG /INHAL Dry Powder Inhaler with sensor, 200 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaler with a 32 X 100 mm tube actuated 2 seconds before inhalation
Trial: 28835058
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg intravenously after general anesthesia induction
Trial: 28835058
Drug: Lidocaine cream
RxNorm normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine cream with endotracheal tube
Trial: 28835058
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dexmedetomidine with lidocaine cream
Trial: 19246310
Drug: Fentanyl (1.6‐1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1.6‐1.8 mg) plus tropisetron (5 mg/100 ml)
Trial: 19246310
Drug: Fentanyl (0.8‐1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.8‐1.0 mg) and flurbiprofen axetil (200 mg) plus tropisetron (5 mg/100 ml)
Trial: 14631327
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus metformin 1000 mg twice a day
Trial: 10847226
Drug: Progesterone cream
RxNorm normalized name: NATURAL PROGESTERONE CREAM,TOP
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone cream 40 mg daily
Trial: 10847226
Drug: Progesterone cream
RxNorm normalized name: NATURAL PROGESTERONE CREAM,TOP
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone cream 20 mg, twice daily
Trial: 10847226
Drug: Progesterone cream
RxNorm normalized name: NATURAL PROGESTERONE CREAM,TOP
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone cream (both regimens)
Trial: 2065637
Drug: Zinc supplement
RxNorm normalized name: Zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplement (22.5 mg daily)
Trial: 6343572
Drug: Indomethacin with
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin with usual medical therapy
Trial: 6343572
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with usual medical therapy
Trial: 6343572
Drug: Indomethacin only
RxNorm normalized name: Indomethacin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin only if usual therapy failed (strategy 2)
Trial: 6343572
Drug: Indomethacin with
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin with initial medical therapy (strategy 1)
Trial: 16038246
Drug: Mw vaccine
RxNorm normalized name: polyethyloxazoline (200000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mw vaccine (1 x 10^9 heat killed bacilli for the first dose, 5 x 10^8 for the second dose, given 6 months apart)
Trial: 16038246
Drug: Mw vaccine
RxNorm normalized name: polyethyloxazoline (200000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mw vaccine (when both patients and contacts received the vaccine)
Trial: 16038246
Drug: Mw vaccine
RxNorm normalized name: polyethyloxazoline (200000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mw vaccine (when only patients received the vaccine)
Trial: 16038246
Drug: Placebo (1/8th
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1/8th dose of normal dose of tetanus toxoid)
Trial: 11929147
Drug: Measured creatinine
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measured creatinine excretion (CrExcr)
Trial: 10336576
Drug: Sibrafiban 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibrafiban 2 mg
Trial: 10336576
Drug: Sibrafiban 5-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibrafiban 5-12 mg
Trial: 10336576
Drug: Sibrafiban 5-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibrafiban 5-7 mg
Trial: 10336576
Drug: Sibrafiban 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibrafiban 12 mg
Trial: 7482386
Drug: benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril 10 mg (BZ 10)
Trial: 7482386
Drug: benazepril 5
RxNorm normalized name: benazepril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril 5 mg/hydrochlorothiazide 6.25 mg (BZ + HCTZ)
Trial: 1963134
Drug: Different drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different drugs for reducing occlusion frequency after coronary artery bypass
Trial: 6440658
Drug: Bacampicillin 4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacampicillin 4.8 g with probenecid 1 g
Trial: 6440658
Drug: Amoxycillin 3
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 3 g with probenecid 1 g
Trial: 18635912
Drug: Kampo (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kampo (combination of ginseng, oriental bezoar, and glycyrrhiza)
Trial: 16847795
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline while maintaining oxytocin infusion
Trial: 16847795
Drug: Oxytocin discontinuation
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin discontinuation
Trial: 16847795
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline and oxytocin
Trial: 14565653
Drug: DVP (daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DVP (daunorubicin 45 mg/m2 daily, days 1, 2 and 3; prednisone 60 mg/m2 daily orally days 1‐35; vincristine 2 mg intravenously on days 1, 8, 15 and 22)
Trial: 14565653
Drug: DATVP (daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DATVP (daunorubicin 60 mg/m2 daily, days 1, 2 and 3; cytarabine 25 mg/m2 intravenous bolus followed by 200 mg/m2 daily as a continuous infusion on days 1‐5; 6-thioguanine 100 mg/m2 orally every 12 h on days 1‐5; vincristine 2 mg intravenously on days 1 and 8; prednisone 60 mg/m2/day orally, days 1‐7)
Trial: 11083681
Drug: Albuterol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (800 microg)
Trial: 22302887
Drug: Caffeine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (500 mg test dose)
Trial: 22302887
Drug: Caffeine metabolism
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine metabolism rate
Trial: 27761556
Drug: Propofol/alfentanil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol/alfentanil (10 µg/kg IV alfentanil)
Trial: 27761556
Drug: Propofol/ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol/ketamine (0.5 mg/kg IV ketamine)
Trial: 24976448
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of rosuvastatin 10 mg with metformin 750 mg
Trial: 24976448
Drug: Monoadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoadministration of rosuvastatin 10 mg
Trial: 24976448
Drug: Monoadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoadministration of metformin 750 mg
Trial: 24976448
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (rosuvastatin, metformin, and coadministration)
Trial: 22212240
Drug: Melatonin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (6 mg administered 30 min prior to exercise)
Trial: 20707767
Drug: Solifenacin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (5 or 10 mg/day, flexibly dosed)
Trial: 402275
Drug: Phentolamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine infusion during surgery with glucose load (20 g)
Trial: 402275
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate solution infusion during surgery with glucose load (20 g)
Trial: 402275
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate solution and phentolamine infusion during surgery (control group)
Trial: 21792057
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine A (0.05%) twice a day plus preservative-free artificial tears four times a day for 4 months
Trial: 19327530
Drug: Diazoxide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide (100 micromol/L)
Trial: 1563054
Drug: Nasal prongs
RxNorm normalized name: SET,INFUSION,5-PRONG BAXTER #L5C4446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal prongs (Group NP, 4 L.min‐1)
Trial: 1563054
Drug: Simple facemask
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple facemask (Group FM, 8 L.min‐1)
Trial: 30135030
Drug: Etifoxine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etifoxine (100 mg)